Covid-19 roundup: Plant-based shot proves safe, 71% ef­fi­ca­cious in PhI­II; Bourla ex­pects an­tivi­ral to launch this ...

4 years ago
Coronavirus

Can a new Eu­ro­pean biotech make an ADC bet­ter than Pad­cev? In­vestors are putting up al­most $100M to find out

4 years ago
Financing

Richard Lern­er, an­ti­body pi­o­neer and long­time pres­i­dent of Scripps Re­search, dies at 83

4 years ago
People

'We're in': Roche and Genen­tech join forces on a multi­bil­lion-dol­lar dis­cov­ery pact with a brash AI up­start

4 years ago
Deals
Bioregnum

Ice­landic bil­lionare's biosim­i­lar com­pa­ny rais­es $450M, preps for Nas­daq launch with SPAC merg­er

4 years ago
Financing
Startups

As­traZeneca grabs PhI­II AT­TR drug from Io­n­is — in­fus­ing $200M cash in­to strug­gling part­ner

4 years ago
Deals

Al­ways busy, Gary Glick re­cruits Or­biMed in a mas­sive $218M Se­ries A for enig­mat­ic da­ta sci­ence biotech

4 years ago
People
Financing

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

4 years ago
People
Special

Transpa­cif­ic AI biotech makes its Se­ries A de­but — putting $86M in the bank

4 years ago
Financing
Startups

Ap­ple Tree Part­ners leaps across the pond to launch a UK biotech look­ing to crack the se­crets of den­drit­ic cells

4 years ago
Financing
Startups

WHO rec­om­mends against the use of con­va­les­cent plas­ma for Covid-19

4 years ago
Coronavirus

Dig­i­tal clut­ter threat­ens phar­ma-to-physi­cian re­la­tion­ships in shift to next era of com­mu­ni­ca­tions

4 years ago
Pharma
Marketing

Klick Health hands out $100 bills in an­nu­al hol­i­day greet­ing that’s turned in­to de­fault re­cruit­ing tool

4 years ago
Pharma
Marketing

Seat­tle biotech clos­es $18M Se­ries B — and ac­quires a com­pa­ny; An­oth­er George Church alum launch­es up­start

4 years ago
News Briefing

FDA slams Reata's kid­ney drug as in­ef­fec­tive ahead of ad­comm meet­ing

4 years ago
Pharma
FDA+

Recor­dati ac­quires EU­SA Phar­ma and its 4 rare dis­ease drugs, but an­a­lysts ques­tion strat­e­gy be­hind the deal

4 years ago
Deals

Bolt Bio goes bust as in­vestors boo sin­gle re­sponse in ear­ly test against HER2-ex­press­ing tu­mors

4 years ago
R&D

Even as boom wanes, a new $200M SPAC is still hop­ing for an­oth­er big score

4 years ago
Financing

Bio­haven shakes up lead­er­ship team as it feels the heat from mi­graine com­peti­tors

4 years ago
People

No­var­tis pe­ti­tions FDA to block 18 gener­ic com­peti­tors for its megablock­buster heart drug un­til 2024

4 years ago
Pharma
FDA+

The 2022 wave com­ing? Top an­a­lyst says Big Phar­ma will have more than $1T avail­able to sat­is­fy its grow­ing ap­petite ...

4 years ago
Deals
Bioregnum

Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new ...

4 years ago
Coronavirus

Gilead re­calls 2 lots of Vek­lury af­ter in­ves­ti­ga­tion con­firms com­plaint of glass par­tic­u­lates

4 years ago
Coronavirus

Keytru­da wins eighth FDA ap­proval of 2021, mov­ing in­to ad­ju­vant and pe­di­atric melanoma set­tings

4 years ago
FDA+
First page Previous page 605606607608609610611 Next page Last page
A service from the Financial Times